ArticleNature immunology2024
Distinct SIV-specific CD8
Abstract read
In one paragraph
Article in Nature immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Renaissance of antiviral CD8Nature reviews. Immunology · 2026Review
- Article
- HIV controllers, lessons learnt from the lymphoid tissues.Current opinion in HIV and AIDS · 2026Review
- The HIV reservoir landscape in elite controllers.Current opinion in HIV and AIDS · 2026Review
- Recapitulating the qualities of HIV-specific CD8 + T cells from spontaneous controllers.Current opinion in HIV and AIDS · 2026Review
- HIV Reservoirs Across Multiple Tissues: From Heterogeneous Mechanisms to Therapeutic Targeting.Microorganisms · 2026Review
- Autologous neutralizing antibodies and polyfunctional T cells contribute to long-term HIV-1 post-intervention control.Nature immunology · 2026Article
- The Implications of HIV-1 Subtypes on Pathogenesis, Reservoirs and Cure Strategies.Current HIV/AIDS reports · 2026Review
- Targeting the pDC/IFN-I axis in HIV-1 immunotherapy.Current opinion in HIV and AIDS · 2026Review
- Transient tissue residency and lymphatic egress define human CD56Nature immunology · 2025Article
- CD8medRxiv : the preprint server for health sciences · 2025Article
- Delineation of the Human Germinal Centre Immune Landscape Using Multiplex Imaging Analysis.Immunology · 2025Article
- Understanding the HIV-specific T-cell response to immune checkpoint blockade: what can we learn from cancer immunotherapy?Current opinion in HIV and AIDS · 2025Review
- Therapeutic CD8Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Immune-mediated strategies to solving the HIV reservoir problem.Nature reviews. Immunology · 2025Review
- Highly immunogenic DNA/LION nanocarrier vaccine potently activates lymph nodes inducing long-lasting immunity in macaques.iScience · 2025Article
- Post-intervention control in HIV immunotherapy trials.Current opinion in HIV and AIDS · 2025Review
- Viral and immune predictors of HIV posttreatment control.Current opinion in HIV and AIDS · 2025Review
- Tissue-Specific DNA Methylation Changes in CD8Viruses · 2024Article
- Dual blockade of IL-10 and PD-1 leads to control of SIV viral rebound following analytical treatment interruption.Nature immunology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
30 authors.
Zachary Strongin *Division of Microbiology and Immunology, Emory National Primate Research Center, Emory University, Atlanta, GA, USA.
Laurence Raymond Marchand *Division of Microbiology and Immunology, Emory National Primate Research Center, Emory University, Atlanta, GA, USA.
Claire DeleageAIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, National Cancer Institute, Frederick, MD, USA.ORCID http://orcid.org/0000-0002-3507-0055
M Betina PampenaDepartment of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0001-6665-4865
Maria Andrea CardenasDepartment of Urology, Emory University School of Medicine, Atlanta, GA, USA.
Christian Michel BeuschDepartment of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA, USA.
Timothy N HoangDivision of Microbiology and Immunology, Emory National Primate Research Center, Emory University, Atlanta, GA, USA.
Elizabeth A UrbanAIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, National Cancer Institute, Frederick, MD, USA.
Mael GourvesInstitut Pasteur, Université Paris Cité, Viral Reservoirs and Immune Control Unit, Paris, France.ORCID http://orcid.org/0009-0002-3947-1523
Kevin NguyenDivision of Microbiology and Immunology, Emory National Primate Research Center, Emory University, Atlanta, GA, USA.
Gregory K TharpDivision of Microbiology and Immunology, Emory National Primate Research Center, Emory University, Atlanta, GA, USA.ORCID http://orcid.org/0000-0003-3075-755X
Stacey LappDivision of Microbiology and Immunology, Emory National Primate Research Center, Emory University, Atlanta, GA, USA.
Andrew R RahmbergBarrier Immunity Section, Laboratory of Viral Diseases, NIAIDNIH, Bethesda, MD, USA.ORCID http://orcid.org/0000-0002-6306-4584
Justin HarperDivision of Microbiology and Immunology, Emory National Primate Research Center, Emory University, Atlanta, GA, USA.ORCID http://orcid.org/0000-0002-6948-3501
Perla M Del Rio EstradaDepartment of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA, USA.
Mauricio Gonzalez-NavarroCentro de Investigación en Enfermedades Infecciosas, Instituto Nacional de Enfermedades Respiratorias, Mexico City, Mexico.
Fernanda Torres-RuizCentro de Investigación en Enfermedades Infecciosas, Instituto Nacional de Enfermedades Respiratorias, Mexico City, Mexico.ORCID http://orcid.org/0000-0002-4296-3740
Yara Andrea Luna-VillalobosCentro de Investigación en Enfermedades Infecciosas, Instituto Nacional de Enfermedades Respiratorias, Mexico City, Mexico.
Santiago Avila-RiosCentro de Investigación en Enfermedades Infecciosas, Instituto Nacional de Enfermedades Respiratorias, Mexico City, Mexico.
Gustavo Reyes-TeranComision Coordinadora de los Institutos Nacionales de Salud y Hospitales de Alta Especialidad, Mexico City, Mexico.
Rafick SekalyDepartment of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA, USA.ORCID http://orcid.org/0000-0002-7816-4828
Guido SilvestriDivision of Microbiology and Immunology, Emory National Primate Research Center, Emory University, Atlanta, GA, USA.ORCID http://orcid.org/0000-0001-6602-2470
Deanna A KulpaDivision of Microbiology and Immunology, Emory National Primate Research Center, Emory University, Atlanta, GA, USA.ORCID http://orcid.org/0000-0002-0411-7295
Asier Saez-CirionInstitut Pasteur, Université Paris Cité, Viral Reservoirs and Immune Control Unit, Paris, France.ORCID http://orcid.org/0000-0003-2406-7536
Jason M BrenchleyBarrier Immunity Section, Laboratory of Viral Diseases, NIAIDNIH, Bethesda, MD, USA.
Steven E BosingerDivision of Microbiology and Immunology, Emory National Primate Research Center, Emory University, Atlanta, GA, USA.ORCID http://orcid.org/0000-0002-2116-5061
David Ezra GordonDepartment of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA, USA.
Michael R BettsDepartment of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0002-7690-1484
Haydn T KissickDepartment of Urology, Emory University School of Medicine, Atlanta, GA, USA.ORCID http://orcid.org/0000-0001-7624-5598
Mirko PaiardiniDivision of Microbiology and Immunology, Emory National Primate Research Center, Emory University, Atlanta, GA, USA. mirko.paiardini@emory.edu.ORCID http://orcid.org/0000-0002-7276-3600
Funding
WORK ORDER 126643 B539 EXPAND IC SUITE75N91019D00024 · NIAID · LEIDOS BIOMEDICAL RESEARCH, INC. · PI BRISCOE, LYNN · 2019 to 2025
$3932.6MYerkes National Primate Research Center Role of type-I IFN in regulating COVID-19 induced inflammation and pathogenesisP51OD011132 · OD · EMORY UNIVERSITY · PI Joon Sup Lee · 2012 to 2026
$167.0MVirology and Molecular Biomarkers CoreP30AI050409 · NIAID · EMORY UNIVERSITY · PI Ann M Chahroudi, Colleen F Kelley · 2002 to 2026
$74.0MERASE HIV: Enterprise for Research and Advancements to Stop and Eradicate HIVUM1AI164562 · NIAID · EMORY UNIVERSITY · PI Deanna A Kulpa, Mirko Paiardini · 2021 to 2026
$30.0MMechanisms of Immune Activation and Disease Progression in Animal ModelsZIAAI001029 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI BRENCHLEY, JASON · 2009 to 2025
$28.2MViral Testing Core-Maintenance of the SPF Breeding Colonies at Yerkes National Primate Research CenterU42OD011023 · OD · EMORY UNIVERSITY · PI Matthew Ryan Gardner · 2018 to 2026
$17.5MHarnessing IL-10 in cART treated SIV infected macaques to restore immunity and to eradicate HIVR37AI141258 · NIAID · EMORY UNIVERSITY · PI Rafick Pierre Sekaly · 2018 to 2026
$7.8MImmune based interventions for HIV eradicationR01AI116379 · NIAID · EMORY UNIVERSITY · PI PAIARDINI, MIRKO · 2015 to 2019
$4.2MIllumina NovaSeq 6000 High Throughput DNA Sequencer for Emory UniversityS10OD026799 · OD · EMORY UNIVERSITY · PI BOSINGER, STEVEN EDWARD · 2019 to 2019
$985kMobilizing host defenses to lymphoid sites of HIV persistence to induce remissionR56AI150401 · NIAID · EMORY UNIVERSITY · PI LEDERMAN, MICHAEL MARCEL, PAIARDINI, MIRKO · 2020 to 2020
$898kDivision of Intramural Research, National Institute of Allergy and Infectious Diseases (Division of Intramural Research of the NIAID) R01AI116379Division of Intramural Research, National Institute of Allergy and Infectious Diseases (Division of Intramural Research of the NIAID) R56AI150401Division of Intramural Research, National Institute of Allergy and Infectious Diseases (Division of Intramural Research of the NIAID) UM1AI164562Intramural NIH HHS ZIA AI001029NCI NIH HHS 75N91019D00024NIAID NIH HHS P30 AI050409NIAID NIH HHS R01 AI116379NIAID NIH HHS R37 AI141258NIAID NIH HHS R56 AI150401NIAID NIH HHS UM1 AI164562NIH HHS P51 OD011132NIH HHS S10 OD026799NIH HHS U42 OD011023U.S. Department of Health & Human Services | National Institutes of Health (NIH) OD026799U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID) 1ZIAAI001029Vetenskapsrådet (Swedish Research Council) 2023-00510
Abstract
Human immunodeficiency virus (HIV) cure efforts are increasingly focused on harnessing CD8
Indexed as
CD8-Positive T-LymphocytesLymph NodesSimian Acquired Immunodeficiency SyndromeSimian Immunodeficiency VirusAnimalsHIV InfectionsHumansMacaca mulattaT-Lymphocyte Subsets
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.